Using extrinsic agents like TRAIL has numerous advantages: Firstly, TRAIL can trigger apoptosis independently of p53, which is commonly mutated in GBM patients [53], contributing, in part, to TMZ resistance [54]; and secondly, TRAIL can kill cancer cells without conferring significant toxicity to normal cells [51]. The gene discussed is TNFSF10; the disease is glioblastoma.